Solid Biosciences to Present at Upcoming Scientific Meetings

Core Insights - Solid Biosciences Inc. is set to present data from its neuromuscular and cardiac programs at two major conferences in October 2025, showcasing the potential of its innovative pipeline and proprietary capsid, AAV-SLB101 [1][2] Conference Presentations - At the World Muscle Society (WMS) 2025 Annual International Congress, the company will present an oral update on the INSPIRE DUCHENNE trial, focusing on SGT-003, a next-generation microdystrophin gene therapy for Duchenne Muscular Dystrophy [2][3] - A poster presentation at WMS will evaluate muscle integrity biomarkers to assess therapeutic efficacy in Duchenne Muscular Dystrophy [3] - At the European Society of Gene & Cell Therapy (ESGCT) 2025 Annual Congress, the company will present on SGT-003 and its innovative AAV-SLB101 capsid [3][6] Company Overview - Solid Biosciences is focused on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, with a diverse pipeline including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, and SGT-501 for catecholaminergic polymorphic ventricular tachycardia [5][7] - The company aims to advance its gene therapy candidates and delivery technologies to significantly impact the field of gene therapy [5][7]